In mice, loss of this signaling axis through pharmacologic inhibition of G-CSF or GM-CSF signaling led to reduced bone cancer pain, reduced peripheral nerve sprouting, and attenuated tumor growth. The gene discussed is CSF2; the disease is bone neoplasm.